¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå : ¾÷°è ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
Mammalian Cell Banking Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»óǰÄÚµå : 1701683
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 251 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,227,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,555,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 12,291,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 5¾ï 6,700¸¸ ´Þ·¯¿¡ ´Þ¤¾¸¶°í, 2025-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 14.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 14¾ï 1,880¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå¿¡´Â »ý¹° ÀǾàǰ Á¦Á¶, À¯ÀüÀÚ Ä¡·á, ¹é½Å Á¦Á¶¿¡ ÇʼöÀûÀÎ Æ÷À¯·ù ¼¼Æ÷ À¯·¡ ¼¼Æ÷ÁÖÀÇ °³¹ß, º¸°ü, À¯Áö°ü¸®°¡ Æ÷ÇԵ˴ϴÙ. ¼¼Æ÷ÀºÇàÀº ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ÀÇ Àϰü¼º, ǰÁú, ¾ÈÀü¼ºÀ» º¸ÀåÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ´ÜŬ·ÐÇ×ü, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á, ¸ÂÃã ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Æ÷À¯·ù ¼¼Æ÷ ÀºÇàÀº ½Å·ÚÇÒ ¼ö ÀÖ°í È®À强ÀÌ ³ôÀº »ý»ê °øÁ¤À» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀåÀº ¸î °¡Áö °­·ÂÇÑ ¿äÀο¡ ÀÇÇØ °­·ÂÇÑ ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡À̸ç, ÀÌ·¯ÇÑ Á¦Á¦´Â »ý»ê¿¡ ¾ÈÁ¤ÀûÀ̰í Àß Æ¯¼ºÈ­µÈ Æ÷À¯·ù ¼¼Æ÷ÁÖ¸¦ ÇÊ¿ä·Î ÇÕ´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾ÈÀüÇÏ°í °íǰÁúÀÇ ¼¼Æ÷ÀºÇà ½Ã½ºÅÛÀÇ Çʿ伺ÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, CRISPR ±â¹Ý ¿£Áö´Ï¾î¸µ ¹× ÇÏÀ̽º·çDz ½ºÅ©¸®´×°ú °°Àº ¼¼Æ÷ÁÖ °³¹ß ±â¼úÀÇ ¹ßÀüµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼Æ÷ÀºÇà¿¡¼­ ¿ì¼öÀǾàǰ Á¦Á¶±âÁØ(GMP) »ç¿ë¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº Á¦Ç° ǰÁú°ú ±ÔÁ¤ Áؼö¸¦ °­È­ÇÏ¿© ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù.

Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀåÀº ¼ºÀå ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ¸î °¡Áö °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ƯÈ÷ Áß¼Ò±â¾÷ÀÇ °æ¿ì, GMP Áؼö ½Ã¼³ ¼³¸³¿¡ µû¸¥ ³ôÀº Ãʱâ ÅõÀÚ ¹× ¿î¿µ ºñ¿ëÀÌ Å« À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ¼¼Æ÷ÁÖ¿¡ ´ëÇÑ º¹ÀâÇÏ°í ½Ã°£ÀÌ ¿À·¡ °É¸®´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ÀýÂ÷´Â Á¦Ç° °³¹ßÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿À¿°, À¯ÀüÀÚ µå¸®ÇÁÆ®, Àå±â º¸°ü ½Ã º¯µ¿°ú °ü·ÃµÈ ¸®½ºÅ©°¡ ÀÖ¾î ¾ö°ÝÇÑ Ç°Áú °ü¸® ¹× ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÌ ÇÊ¿äÇϸç, ÀÌ´Â ºñ¿ë°ú º¹À⼺À» Áõ°¡½ÃŰ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù.

Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀåÀº È®Àå ¹× Çõ½ÅÀÇ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ Á¾¾çÇÐ ¹× Èñ±ÍÁúȯ¿¡¼­ »ý¹°ÇÐÀû Á¦Á¦ ¹× ÷´Ü Ä¡·á¹ýÀ» Æ÷ÇÔÇÑ ÀÓ»ó½ÃÇèÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´Ù¾çÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ¼¼Æ÷ÀºÇà¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï ½ÃÀåÀº ¹ÙÀÌ¿À ÀǾàǰ »ý»ê ´É·ÂÀ» ºü¸£°Ô È®ÀåÇϰí ÀÖÀ¸¸ç, »õ·Î¿î ºñÁî´Ï½º Àü¸ÁÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À Á¦¾à»ç¿Í CRO°¡ ¼¼Æ÷ÀºÇà ¼­ºñ½º¸¦ °øµ¿À¸·Î ¾Æ¿ô¼Ò½ÌÇÏ´Â »ç·Ê°¡ Áõ°¡Çϸ鼭 È®À强°ú È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖÀ¸¸ç, AI¸¦ Ȱ¿ëÇÑ Ç°Áú °ü¸® ¹× µðÁöÅÐ ¹ÙÀÌ¿À¹ðÅ· Ç÷§Æû°ú °°Àº ÀÚµ¿È­ ¹× µðÁöÅÐ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚµµ Ç¥ÁØÈ­¿Í ¿î¿µÀÇ ¿ì¼ö¼ºÀ» ³ôÀÏ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Ç¥ÁØÈ­¿Í ¿î¿µÀÇ ¿ì¼ö¼ºÀ» ³ôÀÏ ¼ö ÀÖ´Â ¹®À» ¿­¾îÁÝ´Ï´Ù.

¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ¼¼Æ÷º°/±â¼úº°/¿ëµµº°/ÃÖÁ¾»ç¿ëÀÚº°/Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Áß¿ä ¼º°ø ¿äÀÎ

Á¦5Àå ½ÃÀå ¹è°æ

Á¦6Àå COVID-19 À§±â - ¿µÇâ Æò°¡

Á¦7Àå ¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â

Á¦8Àå ¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â, ¼¼Æ÷º°

Á¦9Àå ¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á,2019-2032³â, ±â¼úº°

Á¦10Àå ¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-203, ¿ëµµº°

Á¦11Àå ¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â, ÃÖÁ¾»ç¿ëÀÚº°

Á¦12Àå ¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â, Áö¿ªº°

Á¦13Àå ºÏ¹ÌÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â

Á¦14Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â

Á¦15Àå À¯·´ÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â

Á¦16Àå ³²¾Æ½Ã¾ÆÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â

Á¦17Àå µ¿¾Æ½Ã¾ÆÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â

Á¦18Àå ¿À¼¼¾Æ´Ï¾Æ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå

Á¦19Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æ÷À¯·ù ¼¼Æ÷ÀºÇà ½ÃÀå Àü¸Á, 2019³â-2032³â

Á¦20Àå ½ÃÀå ±¸Á¶ ºÐ¼®

Á¦21Àå °æÀï ºÐ¼®

Á¦22Àå ÀüÁ¦¿Í »ç¿ëµÈ µÎÀÚ¾î

Á¦23Àå Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Persistence Market Research has recently released a comprehensive report on the global Mammalian Cell Banking Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Mammalian Cell Banking Market - Report Scope:

The mammalian cell banking market includes the development, storage, and maintenance of cell lines derived from mammalian cells, which are essential for biologics manufacturing, gene therapy, and vaccine production. Cell banks ensure consistency, quality, and safety in the production of biopharmaceuticals. As demand for monoclonal antibodies, cell and gene therapies, and personalized medicine increases globally, mammalian cell banking has become a critical component in ensuring reliable and scalable production processes.

Market Growth Drivers:

The mammalian cell banking market is experiencing strong growth driven by several influential factors. A major driver is the rising demand for biologics and biosimilars, which require stable and well-characterized mammalian cell lines for production. The increasing focus on personalized medicine and cell & gene therapies has further accelerated the need for secure and high-quality cell banking systems. Technological advancements in cell line development, such as CRISPR-based engineering and high-throughput screening, are also contributing to market expansion. In addition, regulatory support for the use of Good Manufacturing Practices (GMP) in cell banking enhances product quality and compliance, propelling the market forward.

Market Restraints:

Despite its growth potential, the mammalian cell banking market faces some challenges. High initial investment and operational costs associated with establishing GMP-compliant facilities can be a significant barrier, especially for small and mid-sized enterprises. Moreover, the complex and time-consuming regulatory approval processes for new cell lines can delay product development. There are also risks associated with contamination, genetic drift, or variability in long-term storage, which necessitate stringent quality control and monitoring systems, adding to the cost and complexity.

Market Opportunities:

The mammalian cell banking market presents numerous opportunities for expansion and innovation. The increasing number of clinical trials involving biologics and advanced therapies, particularly in oncology and rare diseases, is creating demand for diverse and reliable cell banks. Emerging markets in Asia-Pacific and Latin America are rapidly expanding their biopharmaceutical manufacturing capabilities, offering new business prospects. In addition, collaborations between biopharma companies and CROs to outsource cell banking services are on the rise, enabling scalability and efficiency. Investment in automation and digital technologies, such as AI-driven quality control and digital biobanking platforms, also opens doors for greater standardization and operational excellence.

Key Questions Answered in the Report:

Competitive Intelligence and Business Strategy:

Leading companies in the mammalian cell banking market, such as Eurofins DiscoverX Corporation, Merck KGaA, Sartorius Stedim BioOutsource Limited, Charles River Laboratories, and Lonza Group Ltd, are focusing on expanding their GMP-compliant manufacturing facilities and enhancing service portfolios to meet global biopharma demand. Strategic partnerships with biotech firms and academic institutes, along with R&D investments in innovative cell line technologies, are key to maintaining a competitive edge. Companies are also emphasizing quality assurance, contamination prevention, and regulatory alignment to boost client confidence and streamline product development pipelines.

Companies Covered in This Report:

Key Segments Covered in Manufacturing of Industry Research:

Cell Type:

Technology:

Application:

End User:

Region:

Table of Contents

1. Executive Summary

2. Market Overview

3. Key Market Trends

4. Key Success Factors

5. Market Background

6. COVID-19 Crisis - Impact Assessment

7. Global Mammalian Cell Banking Market Outlook, 2019-2032

8. Global Mammalian Cell Banking Market Outlook, 2019-2032 , By Cell

9. Global Mammalian Cell Banking Market Outlook, 2019-2032 , By Technology

10. Global Mammalian Cell Banking Market Outlook, 2019-2032 , By Application

11. Global Mammalian Cell Banking Market Outlook, 2019-2032 , By End User

12. Global Mammalian Cell Banking Market Outlook, 2019-2032 , By Region

13. North America Mammalian Cell Banking Market Outlook, 2019-2032

14. Latin America Mammalian Cell Banking Market Outlook, 2019-2032

15. Europe Mammalian Cell Banking Market Outlook, 2019-2032

16. South Asia Mammalian Cell Banking Market Outlook, 2019-2032

17. East Asia Mammalian Cell Banking Market Outlook, 2019-2032

18. Oceania Mammalian Cell Banking Market 2019-2024 and Forecast 2025-2032

19. Middle East and Africa (MEA) Mammalian Cell Banking Market Outlook, 2019-2032

20. Market Structure Analysis

21. Competition Analysis

22. Assumptions and Acronyms Used

23. Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â